Go Pro
NASDAQ:GRML

Greenland Mines Ltd. Common Stock Q4 2025 Earnings Report

Greenland Mines Ltd. Common Stock logo
$4.48 -0.39 (-8.01%)
As of 09/3/2026 04:00 PM Eastern

Greenland Mines Ltd. Common Stock EPS Results

Actual EPS
$0.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Greenland Mines Ltd. Common Stock Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Greenland Mines Ltd. Common Stock Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Greenland Mines Ltd. Common Stock Earnings Headlines

This sub-5 dollar stock operates next to SpaceX and Blue Origin
A small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, right alongside SpaceX and Blue Origin. It holds a special agreement to use a multi-billion dollar federal launch facility for just $500, and its customer list already includes the Pentagon, Lockheed Martin, and GE Aerospace. Most Wall Street analysts have not caught on yet, but a major milestone could change that soon.tc pixel
See More Greenland Mines Ltd. Common Stock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Greenland Mines Ltd. Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Greenland Mines Ltd. Common Stock and other key companies, straight to your email.

About Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

View Greenland Mines Ltd. Common Stock Profile